Provided by Tiger Trade Technology Pte. Ltd.

GlaxoSmithKline PLC

51.84
-0.5300-1.01%
Post-market: 51.890.0500+0.10%19:45 EDT
Volume:4.64M
Turnover:240.70M
Market Cap:105.34B
PE:13.88
High:52.40
Open:52.17
Low:51.55
Close:52.37
52wk High:61.70
52wk Low:32.38
Shares:2.03B
Float Shares:1.95B
Volume Ratio:1.11
T/O Rate:0.24%
Dividend:1.76
Dividend Rate:3.39%
EPS(TTM):3.74
EPS(LYR):3.74
ROE:43.31%
ROA:9.79%
PB:4.83
PE(LYR):13.88

Loading ...

GSK Executives Reinvest Dividends into Company Shares via Reward Plan

TIPRANKS
·
Jan 13

FACTBOX-Global drugmakers rush to boost US presence as tariff threat looms

Reuters
·
Jan 13

Investing in healthcare can be a win-win proposition

The Smart Investor
·
Jan 13

GSK Advances New First-in-Human Prostate Cancer Drug Into Early Clinical Testing

TIPRANKS
·
Jan 13

Summit Therapeutics Expands Ivonescimab Program With GSK Collaboration

TIPRANKS
·
Jan 12

AnaptysBio Pushes Back Against Lawsuit Over Cancer Drug Jemperli Royalties

Benzinga_recent_news
·
Jan 10

GlaxoSmithKline (GSK) Receives a Buy from Jefferies

TIPRANKS
·
Jan 09

LIXTE Biotechnology Holdings (NASDAQ: LIXT) Expands Ovarian Cancer Trial With MD Anderson and GSK

TIPRANKS
·
Jan 09

GSK's Breakthrough Hepatitis B Therapy Meets Primary Endpoints in Phase 3 Trials, Regulatory Filing Imminent

Stock News
·
Jan 08

GSK Cut to Underweight From Equal-Weight by Barclays

Dow Jones
·
Jan 07

GSK Rises Tuesday, Outperforms Market

Dow Jones
·
Jan 07

European Equities Traded in US as ADRs Rise in Tuesday Trading

MT Newswires Live
·
Jan 07

US Cuts Childhood Vaccine Schedule To 11 Core Shots— What It Means For Vaccine Makers Like Merck And GSK

Benzinga_recent_news
·
Jan 06

GSK's Exdensur Gets Approval in Japan to Treat Severe Asthma, Chronic Rhinosinusitis With Nasal Polyps

MT Newswires Live
·
Jan 06

Top Premarket Decliners

MT Newswires Live
·
Jan 05

GSK Says China Approves Nucala to Treat Adults With Chronic Obstructive Pulmonary Disease

MT Newswires Live
·
Jan 05

Market Chatter: Pfizer, GSK, Others to Raise US Prices on 350 Drugs in 2026

MT Newswires Live
·
Dec 31, 2025

Exclusive-Drugmakers Plan to Raise U.S. List Prices on at Least 350 Drugs, According to 3 Axis Data

THOMSON REUTERS
·
Dec 31, 2025

Exclusive-Drugmakers Raising Prices Include Pfizer, Sanofi, GSK, Novartis and Boehringer Ingelheim, Which Have Pricing Deals With Trump Admin

THOMSON REUTERS
·
Dec 31, 2025

A GSK, AstraZeneca Merger Could Be a Possibility -- Market Talk

Dow Jones
·
Dec 30, 2025